Furthermore, it was discovered that KRAS mutant CRC cells treated with refametinib, a MEK inhibitor, stimulated MIF production and resulted in the activation of STAT3 (signal transducer and activator of transcription 3) and MAPK, which promotes resistance to this medication (167). Here, STAT3 is linked to colorectal carcinoma.